BioPharma Today

Europe's regulators are meeting with key health technology assessment (HTA) bodies and taking steps to make advisory committee meetings more accessible. - FDA added a boxed warning to the anti-blood clotting drug Plavix (clopidogrel), alerting patients and health care professionals that it can be less effective in people who cannot...

Read more

Restanza's New Hope: Advance Life Sciences To Conduct New Pivotal Trials - For Bisphosphonates, What Kind Of News Is No News? - Wuxi PharmaTech Sees Relatively Smooth Sailing Ahead Following Major Losses ...

Read more

Pipeline/RD News Enhancing permeability of tumor vessels might improve drug delivery Pfizer reports disappointing trial results on 2 cancer drugs Study: Avastin fails to boost combo's efficacy in prostate cancer Business Finance Study notes increase in regulatory workload at biotech,... ...

Read more

Heart Ailments Rising In China -- China's Minister Of Health Calls For More Regional Support For Healthcare Reform -- Japan, U.S. Regulators Begin Collaborative Review Pilot With Femoral Stents ...

Read more

AstraZeneca forms branded generics alliance with Torrent Pharmaceuticals - Advance Life Sciences has reached an agreement with FDA on approval path for Restanza - FDA has not found a clear connection between bisphosphonates and risk of bone fractures below the hip but is continuing to review data - Rep. Maurice...

Read more

FDA's Sharfstein tells Congress agency needs more authority over drug safety - Insurers push for enhanced medical cost controls in health reform legislation - Allergan's off-label suit against FDA will continue despite Botox approval for spasticity - Rival Medivation has a "Plan B" for prostate cancer trials if Sanofi-Aventis' cabazitaxel...

Read more

Pipeline/RD News Ischemix begins Phase IIa trial of drug for tissue damage Business Finance Cel-Sci receives Byron's marketing fee for cancer drug candidate Takeda pays Affymax $5 million for anemia drug's milestone AstraZeneca partners with Torrent to launch branded generics... ...

Read more

Insurers will offer proposals to modify health reform legislation to address rising medical costs, AHIP’s Ignagni tells March 10 policy forum in response to HHS Secretary Sebelius’ call to come back to the table. ...

Read more

Article Reprinted from "The Pink Sheet" Daily- March 9,2010 The pharmaceutical industry is seeking a path to participation in social media and the Internet without running afoul of FDA's promotional no-no's and appears willing to help pay for it. Read more... ...

Read more

Facet Says Yes To Abbott's $720 Million Buyout Offer ...

Read more

Drug product reviews will be reassigned as FDA reorganizes its Office of New Drugs. ...

Read more

OrbiMed Leads Series A Financing In Its Second China Start-up -- Japan Sets New Reimbursement Prices For NHI-qualified Drugs; Cuts Average 5.75 Percent -- Korea FDA Sends Precautionary Notice To Doctors For Rosiglitazone -- Perrigo Will Acquire Orion Labs To Reach Australian Market ...

Read more

Article reprinted from The Pink Sheet- March 8, 2010 The generics industry is pushing FDA to create a commissioner-level office dedicated to handling issues related to ANDAs during negotiations over the creation a user fee program for generic drugs. Read more... ...

Read more

In this CNBC interview, PharmAsia News India Bureau Chief Vikas Dandekar discusses the latest developments at Strides Arcolab, Ranbaxy and Biocon. ...

Read more